Study identifier:D419QC00007
ClinicalTrials.gov identifier:NCT04774380
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer (LUMINANCE)
Extensive-stage Small Cell Lung Cancer
Phase 3
-
-
-
152
Interventional
-
Allocation: Non-Randomized
Endpoint Classification: -
Intervention Model: Single Group
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2026 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions |
|---|